The emergence of Retatrutide ZPHC, at a dosage of 120mg, is creating considerable excitement within the healthcare community. This novel dual GIP and GLP-1 target medication suggests to offer significant improvements in weight shedding compared to previous therapies. Early clinical studies have demonstrated significant decreases in body mass , pote